Triple
T20301131
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Imfinzi |
E505480
|
entity |
| Predicate | hasMolecularTarget |
P37016
|
FINISHED |
| Object | CD274 |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: CD274 | Statement: [Imfinzi, hasMolecularTarget, CD274]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: CD274 Context triple: [Imfinzi, hasMolecularTarget, CD274]
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
Nectin-4/CD137 (via BT7480)
Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
D.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
E.
CD340
CD340 is an alternative name for the human epidermal growth factor receptor 2 (HER2), a cell surface receptor tyrosine kinase often overexpressed in certain aggressive breast and gastric cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: CD274 Target entity description: CD274, also known as PD-L1, is an immune checkpoint protein expressed on various cells that helps tumors evade immune detection and is a key target of several cancer immunotherapies.
-
A.
PD-1
PD-1 is an inhibitory immune checkpoint receptor on T cells that downregulates immune responses and is a key target of cancer immunotherapy.
-
B.
CD38
CD38 is a cell surface glycoprotein with ectoenzyme and receptor functions, highly expressed on plasma cells and targeted in therapies for multiple myeloma and other hematologic malignancies.
-
C.
Nectin-4/CD137 (via BT7480)
Nectin-4/CD137 (via BT7480) refers to the tumor-targeted immune agonist mechanism of BT7480, a Bicycle Therapeutics drug candidate designed to engage Nectin-4–expressing cancer cells while activating the CD137 costimulatory receptor to stimulate anti-tumor immune responses.
-
D.
CD21
CD21 is a complement receptor (CR2) found on B cells and follicular dendritic cells that plays a key role in B cell activation and the immune response.
-
E.
CD340
CD340 is an alternative name for the human epidermal growth factor receptor 2 (HER2), a cell surface receptor tyrosine kinase often overexpressed in certain aggressive breast and gastric cancers.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e0b4b8ab648190906e18538c250148 |
completed | April 16, 2026, 10:06 a.m. |
| NER | Named-entity recognition | batch_69e6770c700c81909da247cef0d0f1eb |
completed | April 20, 2026, 6:57 p.m. |
Created at: April 16, 2026, 11:17 a.m.